Villalobos-Alcázar G, Guzmán-Bárcenas J, González-Pérez V, Rojas-Hernández A

Language: Spanish
References: 16
Page: 181-187
PDF size: 138.21 Kb.

ABSTRACT

Introduction: Hyperbilirrubinemia is one of the first 10 morbidity causes in the Intermediate therapy it can produce complications so severe, as nuclear encefalopathy, leaving as sequels mental delay and in cases more severe infantil cerebral paralysis. The objective of the present study, to settle down which are the factors of risk that exacerbate non hemolytic hyperbilirrubinemia in newborn hospitalized on the intermediate therapy unit.
Methodology. We carried out a retrospective study, of cases and controls, during one year, they registered 14 variables recognized as factors promoters in different clinical studies. It was defined hyperbilirrubinemia with serum bylirrubin › 10 mg/dL in the first 24 h. The controls they were selected by gestacional age and weight. One hundred fifty files were revised, 35 were excluded, being a total 115 files: 54 cases and 61 controls. For the analysis we was carried out χ² and odds ratio with CI of 95%.
Results. Of the 54 cases, 33 were preterm and 21 of term, for the group control 24 were preterm and 12 of term. The factors promoters that were significant in the RN preterm were: The Caesarean operation with a RM 16.8 (CI 95% 3.81 - 82.03), the fast with a RM 7.69 (CI 95% 1.87-34.43) with an average of hours of 111.6 ± 72. In second place in both groups the sepsis with RM 16.95 (CI 95% 1.98-377.10).
Conclusions. The factors promoters identified in both groups were the sepsis and the fast. Other factors of risk mentioned in the literature were not significant in this work.

REFERENCES

1. Gartner LM, Lee KS, Vaisman S, Laanee D, Zarafu I. Development of bilirrubin transport and metabolism in the newborn rheusus monkey. J Pediatr 1977; 90: 513-31.

2. Newman TB, Maisels MJ. Evaluation and treatment of jaundice in term newborn. A kinder, gentler approach. Pediatrics 1992; 89: 809-18.

3. Newman TB, Maisels MJ. Does hyperbilirrubinemia damage the brain of healthy full-term infants? Clin Perinatol 1990; 17: 331-58.

4. Watchko JF, Oski FA. Kernicterus in preterm newborns: Past, present, and future. Pediatrics 1992; 90: 707-15.

5. Blackborn S. Hyperbilirrubinemia and neonatal jaundice. Neonatal New 1995; 14: 15-25.

6. Seidman DS, Stevenson DK, Ergaz T, Gale R. Hospital readmission due to neonatal hyperbilirrubinemia. Pediatrics 1995; 96(4 Pt 1): 727-9.

7. Schwoebel A. Sakraida S. Hyperbilirrubinemia: New approaches to an old problem. J Perinat Neonatal Nurs 1997; 11: 78-97.

8. Jeffrey M. Ictericia neonatal. Clínicas de Perinatología 1990; 2: 257-86.

9. Peñaloza LY, Poblano LA, Esquinca CMT. Impacto de la hiperbilirrubinemia neonatal en las funciones cerebrales. En: Ontogenia neural, Salas M, editor. México, D.F. Sociedad Mexicana de Ciencias Fisiológicas. Universidad Nacional Autónoma de México, 1991: 319-330.

10. Catz C, Hanson SW, Simpson L, Yaffe SJ. Summary of workshop: Early discharge and neonatal hyperbilirrubinemia. Pediatrics 1995; 96: 743-45.

11. Poland RL, Odell GB. Physiologic Jaundice. The enterohepatic circulation of bilirrubin. N Engl J Med 1971; 284: 1-6.

12. Chen JY, Ling UP, Chen JH. Early meconium evacuation: efect in neonatal hyperbilirrubinemia. Am J Perinatol 1995; 12: 232-4.

13. Jang HC, Cho NH, Min YK, Han IK, Jung KB, Metzger BE. Increased macrosomia and perinatal morbility independent of maternal obesity and advanced age in Korean women with GMD. Diabetes Care. 1997; 20: 1582-8.

14. Bor M, Ens-Dokkum, Schreuder AM, Veen S, Hyperbilirrubinemia in Low Birth Weight infants and outcome at 5 years of age. Pediatrics 1992; 89; 359-63.

15. Linn S, Schoenbaum SC. Epidemiology of neonatal hyperbilirrubinemia. Pediatrics 1985; 75: 770-4.

16. Friedman L, Lewis PJ, Clifton P. Factors influencing the incidence of neonatal jaundice. Br Med J 1978; 1: 1235-7.